Kyle Gano compensation by year
NEUROCRINE BIOSCIENCES Summary Compensation Table · all 6 fiscal years held| Component | FY2016 | FY2018 | FY2019 | FY2020 | FY2021 | FY2025 |
|---|---|---|---|---|---|---|
| Salary | $345,000 | $403,100 | $443,400 | $487,700 | $517,000 | $920,000 |
| Bonus | $155,250 | $191,473 | $266,040 | $207,273 | $271,425 | $966,000 |
| Stock awards | $1,014,918 | $2,656,575 | $1,000,076 | $2,750,210 | $2,375,067 | $5,750,023 |
| Option awards | $734,916 | $1,309,024 | $3,000,285 | $3,749,799 | $2,625,018 | $5,750,006 |
| Non-equity incentive | $0 | $0 | $0 | $0 | $0 | $0 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 | $0 | $0 |
| All other | $4,363 | $8,069 | $16,171 | $16,751 | $22,814 | $62,906 |
| Total | $2,254,447 | $4,568,241 | $4,725,972 | $7,211,733 | $5,811,324 | $13,448,935 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: NEUROCRINE BIOSCIENCES INC DEF 14A filed April 15, 2026, accession 0000914475-26-000015, and prior-year filings. Open the filing on EDGAR.
How this page was built: the NEUROCRINE BIOSCIENCES INC filed document, accession 0000914475-26-000015. Every figure is read from that document and cited to the page and table it appears in. Filed April 15, 2026.
Equity holdings
unvested awards at FY2025 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| PSU | 29,442 | $4,175,759 | — |
| RSU | 19,628 | $2,783,839 | — |
| RSU | 12,550 | $1,779,967 | — |
| RSU | 9,968 | $1,413,761 | — |
| RSU | 6,725 | $953,807 | — |
| RSU | 5,132 | $727,872 | — |
| PSU | 3,683 | $522,360 | — |
| RSU | 2,927 | $415,136 | — |
| RSU | 1,842 | $261,251 | — |
| Option | 1,661 | — | $79.02 |
| Option | 18,605 | — | $103.52 |
| Option | 24,406 | — | $133.84 |
Per the Outstanding Equity Awards at Fiscal Year-End table in NEUROCRINE BIOSCIENCES INC's FY2025 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 14 award rows shown.
Insider transactions since the last proxy
7 Form 4 lines since the FY2025 proxy (filed April 15, 2026)current to 2026-11-06 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-11-01 | Tax withholding | — | 332 | $146.10 | 155,010 |
| 2026-11-01 | Exercise or conversion derivative | — | 614 | $0.00 | 1,228 |
| 2026-11-01 | Exercise or conversion | — | 614 | $0.00 | 155,342 |
| 2026-09-11 | Grant or award | — | 1,842 | $0.00 | 155,722 |
| 2026-09-11 | Tax withholding | — | 994 | $156.22 | 154,728 |
| 2026-09-11 | Tax withholding | — | 3,386 | $156.22 | 153,880 |
| 2026-09-11 | Grant or award | — | 6,275 | $0.00 | 157,266 |
The 7 most recent of 7 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
NEUROCRINE BIOSCIENCES’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Kyle Gano · this page | Chief Executive Officer and Director | $13,448,935 |
| Sanjay Keswani | Chief Medical Officer | $9,007,803 |
| Jude Onyia | Chief Scientific Officer | $7,410,769 |
| Matthew Abernethy | Chief Financial Officer | $6,311,912 |
| Eiry Roberts | Strategic Advisor | $6,073,032 |
| Eric Benevich | Chief Commercial Officer | $5,888,947 |
Board service
NEUROCRINE BIOSCIENCES board · FY2024–FY2025How this board is paid
Company policy: NEUROCRINE BIOSCIENCES pays directors a $60,000 cash retainer and $400,000 in RSUs/Options. As stated in NEUROCRINE BIOSCIENCES's FY2025 proxy.
The full NEUROCRINE BIOSCIENCES compensation record
free company briefThis page is one person within NEUROCRINE BIOSCIENCES's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the NEUROCRINE BIOSCIENCES proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order NEUROCRINE BIOSCIENCES's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are NEUROCRINE BIOSCIENCES's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order NBIX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.